McKesson

Strategic Intent

McKesson Corporation operates as a global leader in healthcare supply chain management, pharmaceutical distribution, and oncology care services, providing the critical infrastructure and technology that connects biopharma manufacturers with providers and patients.

Key Market Signals

• 2026-03: Participation in Barclays Global Healthcare Conference to discuss FY2026 performance and strategy
• 2026-03: Confirmation of quarterly dividend payment for shareholders of record as of March 2, 2026
• 2026-01: Reaffirmation of full-year 2026 financial outlook following strong Q3 results
• 2025-09: Implementation of new organizational structure focusing on North American Pharmaceutical and Oncology segments
• 2025-06: Completion of $2.49 billion acquisition of controlling interest in Florida Cancer Specialists' Core Ventures

Financial Health

• Reported Q3 Fiscal 2026 revenue of $106.16 billion, an 11.4% increase year-over-year (Source: MarketBeat reporting on Feb 2026 earnings)
• Raised Fiscal 2026 full-year Adjusted EPS guidance to a range of $38.80 to $39.20 (Source: McKesson Investor Relations, Feb 2026)
• Declared a quarterly dividend of $0.82 per share, payable April 1, 2026 (Source: McKesson Press Release, Jan 2026)

Impact & Compliance

Legal & Risks

McKesson faces ongoing oversight from multi-billion dollar opioid settlements and recently finalized a $152 million payout to the City of Baltimore in August 2025. The company also settled systemic hiring discrimination allegations with the U.S. Department of Labor in November 2024.

Forensic Audit — 1 findings

• Baltimore jury found McKesson liable for contributing to the city's opioid crisis in November 2024, leading to a $152M f...

Classifications

Proprietary Analysis